Apollomics Inc./$APLM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
Ticker
$APLM
Sector
Primary listing
Employees
14
Headquarters
Website
Apollomics Inc. Metrics
BasicAdvanced
$31m
-
-$7.57
1.52
-
Price and volume
Market cap
$31m
Beta
1.52
52-week high
$42.12
52-week low
$3.66
Average daily volume
9.3k
Financial strength
Current ratio
0.957
Quick ratio
0.911
Long term debt to equity
-13.614
Total debt to equity
-20.169
Interest coverage (TTM)
-140.48%
Profitability
EBITDA (TTM)
-9.085
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-123.72%
Operating margin (TTM)
-103.27%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-57.61%
Return on equity (TTM)
-1,305.37%
Valuation
Price to revenue (TTM)
2.283
Price to book
-9.4
Price to tangible book (TTM)
-9.4
Price to free cash flow (TTM)
-1.947
Free cash flow yield (TTM)
-51.37%
Free cash flow per share (TTM)
-7.171
Growth
Revenue change (TTM)
776.31%
Earnings per share change (TTM)
-85.67%
3-year revenue growth (CAGR)
105.69%
3-year earnings per share growth (CAGR)
-79.24%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs